Galmed Pharmaceuticals Ltd. filings document the company’s foreign private issuer reporting, Aramchol development disclosures and public-company governance matters. Recent Form 6-K reports furnish press releases on Aramchol-based collaborations, brain-penetrating formulation work, scientific presentations, Nasdaq minimum bid price correspondence and shareholder meeting materials.
The filing record also includes proxy and voting materials for special general meetings, incorporation of selected 6-K disclosures into Form S-8 and Form F-3 registration statements, and references to the company’s ordinary shares. These documents describe governance procedures, capital-market registration matters, listing-status communications and development updates for Galmed’s clinical-stage biopharmaceutical business.
Galmed Pharmaceuticals filed a prospectus supplement registering up to 7,500,000 ordinary shares for resale by YA II PN, LTD.
Separately, Galmed entered into a Share Purchase Agreement dated June 8, 2026 to acquire 100% of Colospan Ltd. Consideration includes $2,500,000 cash and $2,000,000 in Galmed ordinary shares (valued using the five-day average Purchaser Share Value). The SPA includes a 4.99% beneficial ownership blocker, an escrow holding 7.5% of each cash and share consideration for 12 months, and contemplates at least $6 million of investment in Colospan commercial expansion over 24 months. Closing is conditioned on Israeli procedural requirements (Section 341) and customary conditions, with closing expected in the second quarter of 2026.
Galmed Pharmaceuticals entered a Share Purchase Agreement to acquire all shares of Colospan Ltd., an Israeli medical device company focused on colorectal surgical care. Closing is expected in the second quarter of 2026, subject to customary conditions.
Galmed will pay $2.5 million in cash and issue $2 million of ordinary shares to Colospan shareholders and SAFE investors, with 7.5% of each held in escrow for 12 months. Galmed also plans to invest at least $6 million over 24 months after closing to build Colospan’s European and Israeli commercial footprint.
Colospan’s lead product, the CG-100 intraluminal bypass device, aims to reduce complications from anastomotic leaks in colorectal surgery. It holds CE Marking, Israeli approval, and FDA Breakthrough Device designation, with a pivotal PMA-supporting trial underway. Colospan remains pre-revenue, has an accumulated deficit, and its auditors highlight substantial doubt about its ability to continue as a going concern.
Galmed Pharmaceuticals Ltd. filed a Form 6-K highlighting new preclinical data from its collaboration with Tissue Dynamics on Aramchol Meglumine for cardiac fibrosis. Using human cardiac organoid models on the DynamiX® platform, researchers identified a previously unknown metabolic pathway linked to cardiac fibrosis and heart failure.
The combination of Aramchol Meglumine, an SCD1 inhibitor, with a selective PPARα agonist reduced fibrotic burden in inflammatory human cardiac organoids by approximately fourfold (p<0.001) while preserving heart muscle structure and metabolic function. A new patent application has been filed and preparations are underway for future IND-enabling activities, supporting Galmed’s strategy to expand Aramchol beyond liver disease into cardiometabolic and fibrotic indications.
Galmed Pharmaceuticals reported Phase 1 pharmacokinetics results for a new oral formulation of Aramchol meglumine (AM). A single 400mg AM dose increased Aramchol bioavailability by about 500% compared with a 300mg Aramchol free acid (AA) tablet, while a 200mg AM dose showed roughly threefold higher exposure.
The company views Study AM-001 as a pivotal step toward a once-daily 400mg AM regimen, supporting production of a GMP clinical batch, extended intellectual property protection, and a potential ~50% reduction in drug manufacturing costs. An additional PK study (AM-003) is ongoing, comparing 400mg AM tablets once daily with 300mg AA tablets twice daily.
Aramchol has previously shown reduced liver fat, attenuation of steatohepatitis, and anti-fibrotic effects at a 600mg dose in Phase 2 and Phase 3 (open-label) trials, with around 600 adults exposed so far. Galmed aims to advance Aramchol beyond MASH into gastrointestinal oncology and other cardiometabolic and neurological indications.
Galmed Pharmaceuticals Ltd. is collaborating with Tissue Dynamics Ltd. to develop a human-centered chronic cardiac fibrosis platform using vascularized, sensor-embedded cardiac organoids to support discovery of new Aramchol-based therapies for complex fibrotic heart diseases.
The platform leverages Tissue Dynamics’ DynamiX® system, which can test more than 20,000 human cardiac organoids in parallel with continuous metabolic sensing and AI analysis. Galmed plans to apply its SCD1 and lipid-metabolism expertise to evaluate Aramchol-based candidates, combinations, and dosing strategies in chronic post-myocardial infarction and HFpEF-like settings.
Galmed Pharmaceuticals Ltd. is entering a research collaboration with Ramot at Tel Aviv University to evaluate its brain-penetrating SCD1 inhibitor Aramchol as a targeted therapy for metastatic brain cancers, particularly in p53-deficient tumors.
The project combines genomic expertise from the Ben-David Lab with advanced 3D in vitro and in vivo tumor models from the Satchi-Fainaro Lab to validate Aramchol’s efficacy and mechanism of action. Findings are also expected to support Galmed’s ongoing clinical work in colorectal cancers, while fitting the company’s strategy to extend Aramchol beyond liver disease into oncology and other cardiometabolic indications.
Galmed Pharmaceuticals reported a scientific milestone: a new brain-penetrating formulation of its SCD1 inhibitor Aramchol, co-developed with Barcode Nanotech. The formulation uses lipid nanoparticles and is designed for subcutaneous injection to cross the blood–brain barrier and reach the central nervous system.
In vitro studies showed that Aramchol dose-dependently down-regulated aggregation of the protein α‑synuclein, which is implicated in Parkinson disease, multiple system atrophy, dementia with Lewy bodies and other synucleinopathies. These disorders currently lack disease-modifying therapies, so a brain-targeted SCD1 inhibitor could represent a new treatment approach.
Galmed plans, subject to regulatory advice, to advance this brain-penetrant Aramchol into a proof-of-concept Phase 1b/2 study in Parkinson disease patients in H2 2026, extending its strategy beyond liver and cardiometabolic indications into chronic CNS diseases with high unmet need.
Galmed Pharmaceuticals Ltd. files its Form 20-F annual report for the year ended December 31, 2025, detailing continued operating losses and substantial doubt about its ability to continue as a going concern.
The company is refocusing lead drug Aramchol from NASH and fibrosis toward oncological and cardiometabolic indications, while acknowledging it has no approved products and limited commercialization experience. For 2024 and 2025, losses attributable to ordinary shareholders were approximately $7.5 million and $10.3 million, respectively, leading to an accumulated deficit of $210.8 million as of December 31, 2025.
Galmed reports net working capital of $15.8 million, including $4.0 million in cash and cash equivalents, $7.1 million in short-term deposits and $7.0 million in marketable debt securities, which it currently expects to fund operations for more than 12 months. Management warns that additional capital will be required, highlights constraints under the Form F-3 Baby Shelf Rule, and discloses potential shareholder dilution from outstanding warrants, options and RSUs. The report emphasizes extensive clinical, regulatory, financing and market risks, including dependence on Aramchol, uncertainty in NASH regulatory pathways, reliance on third parties and exposure to geopolitical risk in Israel.
Galmed Pharmaceuticals Ltd. director David Sidransky filed an initial ownership report showing his equity position in the company. He directly holds 11,083 Ordinary Shares, along with several awards of Restricted Share Units (RSUs) that vest between 2026 and 2028, subject to his continued service.
The filing also lists stock options to purchase 111 Ordinary Shares at an exercise price of 558, expiring in 2031, and options on 166 Ordinary Shares at an exercise price of 2,080.8, expiring in 2028. The entry records holdings rather than new buy or sell transactions.